Wells Fargo & Company Initiates Coverage on Quest Diagnostics Incorporated (DGX)

Lloyd Doyle
October 13, 2017

In this case, shares are down -19.05% from $112.96, the 52-week high touched on Jul. 03, 2017, and are keeping their losses at 9.77% for the past 12 months.

06/26/2017 - Quest Diagnostics Incorporated had its "in line" rating reiterated by analysts at Evercore ISI.

06/12/2017 - Quest Diagnostics Incorporated had its "buy" rating reiterated by analysts at Canaccord Genuity.

Amid volatile financial markets and the presidential election, various investment brokerages have made amendments to their price targets and ratings on shares of Quest Diagnostics Incorporated (NYSE:DGX). Bank of America upgraded the shares of DGX in report on Tuesday, July 25 to "Buy" rating. Mizuho maintained it with "Neutral" rating and $88 target in Friday, October 21 report. Inside the closing six months period the stock's performance declined -6.80% while overall yearly performance gained 9.77%. Denali Advisors Llc acquired 13,700 shares as Quest Diagnostics Inc (DGX)'s stock rose 10.72%. They now have a United States dollars 102 price target on the stock. Therefore 75% are positive. Netlist had 6 analyst reports since September 1, 2015 according to SRatingsIntel. The rating was maintained by Mizuho on Thursday, October 22 with "Neutral". As per Thursday, September 17, the company rating was upgraded by Zacks. The rating was maintained by Raymond James with "Buy" on Monday, June 26.

Since June 5, 2017, it had 0 insider purchases, and 2 sales for $5.12 million activity.

Netlist, Inc. designs, manufactures and sells a range of memory subsystems for datacenter, data storage and computing markets. As per Wednesday, May 11, the company rating was maintained by RBC Capital Markets. About 169,964 shares traded. It has outperformed by 0.16% the S&P500.

Investors sentiment decreased to 0.99 in 2017 Q2. Its down 1.33, from 1.83 in 2017Q1. It dropped, as 38 investors sold DGX shares while 200 reduced holdings. 2 funds opened positions while 2 raised stakes. Ahl Llp has invested 0.02% of its portfolio in Evertec Inc (NYSE:EVTC). (NASDAQ:NLST) for 31,863 shares.


Facebook, Inc. (NASDAQ:FB) is another stock that is grabbing investors attention these days. Its up 5.11% from 4.99M shares previously. Lowe Brockenbrough And Inc holds 28,420 shares or 0.5% of its portfolio. (NASDAQ:NLST) for 76,413 shares. (NASDAQ:NLST) for 18,103 shares. Westwood Grp holds 0.01% or 24,030 shares. The institutional investor owned 346,697 shares of the medical research company's stock after acquiring an additional 1,400 shares during the quarter. Barclays Pcl has invested 0% of its portfolio in Netlist, Inc. Exane Derivatives accumulated 16 shares. Eqis Capital Management, Inc. controls 5,444 shares valued at $510,000. Martingale Asset Limited Partnership stated it has 0.07% in Evertec Inc (NYSE:EVTC). (NASDAQ:CAR). Ing Groep Nv holds 0.01% or 10,247 shares in its portfolio.

Capital World Investors decreased its stake in Merck And Co Inc (MRK) by 10.8% based on its latest 2017Q2 regulatory filing with the SEC. Canandaigua National Bank & Trust And holds 74,674 shares or 0.98% of its portfolio. Canaccord Genuity maintained Quest Diagnostics Inc (NYSE:DGX) on Friday, November 13 with "Buy" rating. The medical research company reported $1.55 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.42 by $0.13. DGX's profit will be $195.94 million for 16.00 P/E if the $1.43 EPS becomes a reality.

More notable recent Quest Diagnostics Inc (NYSE:DGX) news were published by: Barrons.com which released: "Quest Diagnostics: Will It Fail The Test?" on September 25, 2017, also Barrons.com with their article: "The Big Loser: Quest Diagnostics Quits" published on September 25, 2017, Nasdaq.com published: "Quest Diagnostics Inc (DGX) Chairman, President and CEO Stephen H Rusckowski ..." on September 14, 2017. The company has market cap of $441.75 million. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. Also, it has an estimated price-earnings (P/E) multiple of 15.57 and a trailing 12-month price-earnings (P/E) multiple of 18.3. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Investors sentiment decreased to 0.99 in Q2 2017. Its up 0.33, from 1.27 in 2017Q1.

Quest Diagnostics (NYSE:DGX) last posted its earnings results on Tuesday, July 25th. 78 funds opened positions while 158 raised stakes. State Street Corp lifted its stake in shares of Quest Diagnostics by 2.7% during the 1st quarter. The value of the company's investment in Quest Diagnostics Incorporated went from $2,133,000 to $2,880,000,000 a change of $2,877,867,000 since the last quarter. (NYSE:MRK). Vident Investment Advisory Ltd Llc has 20,324 shares. Rand Wealth Lc has 18,223 shares. Daiwa Sb Invests holds 0% of its portfolio in Quest Diagnostics Inc (NYSE:DGX) for 90 shares. Manchester Capital Mngmt Ltd Co owns 250 shares. Swiss Savings Bank invested in 570,530 shares. Mercer Cap Advisers has invested 0.09% of its portfolio in Quest Diagnostics Inc (NYSE:DGX). Schwab Charles Inv Mgmt Incorporated has invested 0.05% in Quest Diagnostics Inc (NYSE:DGX). Klingenstein Fields And Ltd Liability Company holds 4,000 shares.

About 58,371 shares traded. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/12/quest-diagnostics-incorporated-dgx-rating-lowered-to-buy-at-goldman-sachs-group-inc-the.html. It has outperformed by 22.34% the S&P500.

Receive Quest Diagnostics Incorporated News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated with MarketBeat.com's FREE daily email newsletter.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER